Pharmaceutical composition for providing treatment for or preventing alport syndrome

A method for the treatment of Alport syndrome, comprising administering a compound represented by the following general formula (I) or (II), or a pharmaceutically acceptable salt thereof, to a subject in need thereof:

• wherein
• A is a C6-C10 aryl group or a heteroaryl group, wherein at least one hydrogen atom of the aryl group or the heteroaryl group is optionally replaced with a substituent selected from the group consisting of a halogen atom, a hydroxy group, a C1-C6 alkyl group, a C1-C6 haloalkyl group, a C2-C6 alkenyl group, a C2-C6 alkynyl group, a C1-C6 alkoxy group, a C1-C6 haloalkoxy group, a C3-C6 cycloalkyl group, a C3-C6 cycloalkenyl group, a C3-C6 cycloalkoxy group, a heterocyclyl group, a heteroaryl group optionally substituted by a C1-C6 alkyl group, a cyano group, a carboxyl group, a carbamoyl group, a C1-C6 alkoxycarbonyl group, a C1-C6 alkylsulfanyl group, and a C1-C6alkylsulfonyl group,
• R is a hydrogen atom or a C1-C6 alkyl group,
• R1 is a hydrogen atom or a halogen atom, and
• Y is a hydrogen atom, a fluorine atom or a hydroxy group.